References
- Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al. Calprotectin is stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364–8.
- Vestergaard TA, Nielsen SL, Dahlerup JF, Hornung N. Fecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest 2008;68:343–7.
- Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis 2008;23:985–92.
- Rizzello F, Gionchetti P, D’Arienzo A, Manguso F, Di Matteo G, Annese V, et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002;16:1109–16.
- Best WR. Predicting the Crohn's disease activity index from the harvey-bradshaw index. Inflamm Bowel Dis 2006;12: 304–10.
- Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomised study. N Engl J Med 1987;317:1625–9.
- D'Haens G, Ferrante M, Vermeire S, Baert F, Norman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218–24.
- Tøn H, Brandsnes Ø, Dale S, Holtlund J, Skuibina E, Schjønsby H, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41–54.